EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

European Management of Glanzmann's Thrombasthenia: A Survey of Current Clinical Practice

Mathieu Fiore iD, Andrea Artoni, Robert Klamroth iD, Mary Mathias, Roger Schutgens iD, Roseline d'Oiron iD, EAHAD Glanzmann Thrombasthenia Working Group

Haemophilia · 2025-11 · 31 (6) · 1261-1270

DOI: 10.1111/hae.70114 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, online erschienen am 11.09.2025. Verfasst von Mathieu Fiore und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, University Hospital of Bordeaux, Pessac, France. Hauptthemen laut MEDLINE: Thrombasthenia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Glanzmann's thrombasthenia is a rare inherited platelet disorder characterized by a lack of platelet aggregation. Patients tend to be diagnosed in early childhood with treatment strategies involving a multifaceted approach to prevent and manage bleeding episodes. Unfortunately, there is currently no European consensus regarding the management of GT.

Aim

This initiative aimed to gain an understanding of current clinical management of GT across Europe, with the aim of aligning best practice and improving patient outcomes.

Methods

The authors, on behalf of the EAHAD Glanzmann Working Group, administered an online survey of 57 questions to European haematologists currently involved in the management of patients with GT. The survey covered topics related to diagnosis, treatment access and selection, immunization, peri‐operative management and use of second‐line therapies.

Results

Responses reflected physician consensus around some topics, including peri‐operative treatment, use of recombinant factor VIIa, and concerns around antibody development. However, more varied responses were received on topics such as antibody screening (anti‐ αIIbβ3 antibodies screening conducted by ≤53% of respondents in all countries of interest except France), access to HLA‐matched platelet concentrates (none or limited for 55% of respondents) and duration of platelet transfusions for major surgery (13%–31% for 1, 2, 3 and 4 or more days of transfusions).

Conclusion

Establishing comprehensive guidelines to manage GT will enhance patient outcomes by ensuring patients receive high‐quality and effective care as well as standardize care across different healthcare settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThrombastheniaHumansEuropeSurveys and QuestionnairesPlatelet TransfusionDisease ManagementFactor VIIa

Stichwörter der Autor:innen

Glanzmann's diseaseGlanzmann's thrombastheniaclinical practicereal‐world datasurvey

Substanzen

Factor VIIa

Autor:innen und Institutionen

  • Department of Haematology, University Hospital of Bordeaux, Pessac, France.
  • Biology of Cardiovascular Disease, Inserm U1034, Pessac, France.
  • French Reference Centre For Inherited Platelet Disorders, University Hospital of Bordeaux, Pessac, France.
  • Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Department of Internal Medicine, Hemophilia Treatment Center, Vivantes Klinikum im Friedrichshain, Berlin, Germany.
  • Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.

ORCID-Profile: Mathieu Fiore, Robert Klamroth, Roger Schutgens, Roseline d'Oiron

Förderung

  • Novo Nordisk

Zitieren

APA

Fiore, M., Artoni, A., Klamroth, R., Mathias, M., Schutgens, R., d'Oiron, R., & EAHAD Glanzmann Thrombasthenia Working Group (2025). European Management of Glanzmann's Thrombasthenia: A Survey of Current Clinical Practice. Haemophilia, 31(6), 1261-1270. https://doi.org/10.1111/hae.70114

Vancouver

Fiore M, Artoni A, Klamroth R, Mathias M, Schutgens R, d'Oiron R, et al. European Management of Glanzmann's Thrombasthenia: A Survey of Current Clinical Practice. Haemophilia. 2025;31(6):1261-1270. doi:10.1111/hae.70114

BibTeX
@article{Fiore2025,
  author = {Fiore, Mathieu and Artoni, Andrea and Klamroth, Robert and Mathias, Mary and Schutgens, Roger and d'Oiron, Roseline and EAHAD Glanzmann Thrombasthenia Working Group, EAHAD Glanzmann Thrombasthenia Working Group},
  title = {European Management of Glanzmann's Thrombasthenia: A Survey of Current Clinical Practice},
  journal = {Haemophilia},
  year = {2025},
  volume = {31},
  number = {6},
  pages = {1261--1270},
  doi = {10.1111/hae.70114}
}
Kostenlos starten →